White Mulberry Leaves Extract Market Intelligence: Size, Share and Growth Outlook Through 2035

Market Overview

Size, history, and mix

• Brevintel analysis values the white mulberry leaves extract market at USD 51.5 billion in 2025 ($51.5B), rising toward USD 167.6 billion by 2035 ($167.6B).
• The narrative path expands at a 12.5% CAGR over 2026 to 2035, while headline cards also list 12.63% alongside $51.5B and $167.6B.
• Industry data suggests the market reaches USD 58 billion in 2026 before the longer climb through 2035.
• Value expanded from USD 35.6 billion in 2022 to USD 45.8 billion in 2024 at a 13.43% historic CAGR.
• The forecast trajectory adds USD 109.6 billion between 2026 and 2035 as premium specifications and channel access preserve double-digit expansion.
• Shaanxi Bolin Biotechnology led with over 9.8% share in 2025; the top five held 38.5% and the remaining 61.5% sat with regional and specialty suppliers.
• Demand now extends beyond botanical supplementation because 1-deoxynojirimycin (DNJ) gives glycemic-management products a measurable formulation rationale.
• Revenue also comes from cosmetics, functional food, and pharmaceutical uses, reducing dependence on any single downstream purchasing cycle.

Scope and specification shift

• Commercial supply covers powder, liquid, capsule, and other formats derived from Morus alba leaves, sold as standardized and non-standardized extracts.
• The scope includes dietary supplements, food and beverage, cosmetics and personal care, pharmaceuticals, and smaller specialty uses, excluding finished goods whose value does not accrue to the extract itself.
• DNJ inhibits intestinal alpha-glucosidase, a mechanism relevant to post-meal carbohydrate absorption and blood-sugar-management positioning cited by the World Health Organization (WHO).
• Buying conversations are shifting from raw leaf volume toward HPLC verification, cGMP production, organic qualification, and higher DNJ concentrations.
• That documentation shift supports premium pricing where pharmaceutical, clinical nutrition, and high-end cosmetics buyers need repeatable performance.
• Brevintel analysis finds the central constraint is consistent DNJ content with credible quality files, not consumer interest alone.
• Higher-specification products are expected to capture a growing share of value through 2028 as buyers shorten supplier lists around traceability and formulation performance.
• High-potency DNJ extracts have more commercial relevance than commodity powders because they reduce the mass of ingredient needed per finished dose.

Market Dynamics

Demand drivers

• Diabetes prevalence creates an addressable need for glucose-management positioning; the International Diabetes Federation projects 783 million adults with diabetes by 2045.
• DNJ gives ingredient buyers a technical basis for differentiation, although marketing claims remain subject to jurisdiction-specific rules.
• Suppliers that can link agronomy, extraction yield, and analytical release testing are better placed to secure repeat procurement.
• Preventive-health spending broadens demand beyond diagnosed patients; the global wellness economy was valued at more than USD 5.6 trillion.
• That spending does not automatically become extract revenue; brands still need formats, claims support, and channel access, favoring suppliers that offer formulation help.
• Supercritical CO2 can reduce solvent-residue concerns, while enzymatic processing and HPLC testing improve reproducibility.
• Higher active-content density can reduce dosage mass, allowing use in capsules, sachets, beverages, and compact cosmetic formulations.
• Cosmetics buyers value tyrosinase-inhibiting flavonoids, while supplement and medical-food buyers focus on glucose-management formulations.

Constraints and uneven gains

• Mulberry-leaf quality varies with maturity, harvest timing, and agronomic conditions, making raw-material consistency a recurring cost issue.
• Advanced extraction systems and HPLC quality-control programs add capital and recurring laboratory expense, splitting premium and commodity supply.
• Qualification cycles can become a barrier to entry rather than a routine compliance task for smaller processors.
• Awareness limits conversion where supplement retail and practitioner education remain less developed, and purchasing power varies sharply across emerging economies.
• E-commerce improves access but cannot substitute for credible product education or localized regulatory communication.
• Brevintel analysis finds demand drivers outweigh restraints through 2035, but gains will accrue unevenly across the supply base.
• Production cost and qualification requirements will favor suppliers with integrated sourcing and analytical capabilities through 2028.
• Market growth should therefore coexist with wider separation between premium, documented supply and price-led commodity production.

Segmentation Analysis

Form

• Powder was the largest form, holding 45.3% of revenue and reaching USD 23.3 billion in 2025 on transport stability, storage efficiency, and tablet, capsule, beverage, and cosmetic compatibility.
• Suppliers offer concentration-ratio products alongside DNJ-standardized grades, allowing brands to choose between cost-oriented and active-content-led procurement.
• Shaanxi Bolin Biotechnology, Shaanxi Hongda Phytochemistry, and Undersun Biomedtech participate in powder with graded extract portfolios.
• Through 2035, powder will retain its central position, although premium value growth will depend more on HPLC-certified standardization than raw-volume expansion.
• Liquid extracts held 35.2% of revenue, equivalent to USD 18.2 billion in 2025, and will grow at a 12.63% CAGR through 2035.
• Serums, toners, lotions, herbal teas, wellness shots, and ready-to-drink products create the liquid demand base, with pH, preservative, and microbiological controls supporting specification premiums.
• Capsules accounted for 11.5% of market value, or USD 5.9 billion, in 2025 and will expand at an 11.89% CAGR through 2035.
• Jeeva Organic markets a 1% DNJ HPLC-verified extract, while Phytotech Extracts uses the Iminosol brand to distinguish its Morus alba ingredient in capsule-ready supply.
• Other forms, including soft gels, gummies, sachets, and powder sticks, held 8.0% of the market at USD 4.1 billion in 2025 and will expand at a 12.40% CAGR.
• Through 2028, format innovation in gummies and stick packs will create more finished-product differentiation than basic concentration ratios alone.

Application

• Cosmetics and personal care was the largest application, holding 30.6% market share and reaching USD 15.8 billion in 2025, and will expand at a 12.83% CAGR through 2035.
• Rutin, quercetin, and related compounds support skin-brightening, antioxidant, and anti-inflammatory positioning, while tyrosinase inhibition aligns with even-tone products.
• Dietary supplements represented 24.9% of market value, or USD 12.8 billion, in 2025, and will grow at a 12.45% CAGR through 2035 on blood-sugar-management and weight-wellness positioning.
• U.S. Food and Drug Administration (FDA) dietary-supplement rules shape how brands position botanical ingredients and raise the value of identity and active-content files.
• Pharmaceuticals accounted for 20.5% of revenue, or USD 10.6 billion, in 2025 and will be the fastest-growing application at a 12.90% CAGR through 2035.
• Pharmaceutical-intent demand raises qualification costs but can support higher-value contracts through the 2027 to 2032 development window.
• Food and beverage held 14.5% of revenue, or USD 7.5 billion, in 2025 and will expand at an 11.95% CAGR through 2035 in teas, wellness shots, bars, cereals, and extract-infused drinks.
• Through 2030, high-concentration liquids and powder dispersions will be most relevant where beverage manufacturers need small-volume dosing without sensory failure.
• Other applications, including animal nutrition, agricultural uses, and emerging research categories, represented 9.5% of market value at USD 4.9 billion in 2025 and will grow at an 11.64% CAGR.
• Brevintel analysis finds segment value migrating toward applications that reward measurable active content and formulation support rather than bulk botanical volume.

Distribution channel

• E-commerce and online platforms were the largest channel, holding 35.5% share and reaching USD 18.3 billion in 2025, and will grow at a 12.74% CAGR through 2035.
• Digital platforms connect health-focused consumers with branded supplements and help business buyers find suppliers beyond established distributor networks.
• Direct sales accounted for 24.5% of the market, or USD 12.6 billion, in 2025 and will grow at a 12.18% CAGR as brand and formulation customers audit specification-led supply.
• Offline retail held 22.5% of revenue, or USD 11.6 billion, in 2025 and will be the fastest-growing defined channel at a 12.87% CAGR.
• Pharmacy, grocery, specialty health stores, and natural-product retailers remain important discovery points, especially where digital commerce is still maturing.
• Other channels, including wholesalers, practitioner dispensing, and institutional procurement, represented 17.5% of market value at USD 9.0 billion in 2025 and will grow at a 12.04% CAGR.
• Practitioner dispensing has particular relevance for pharmaceutical-grade and clinical-nutrition products that need documentation and dosage consistency.
• By 2030, suppliers that sell technical documentation and formulation reliability alongside extract volume will be better positioned than those competing on concentration ratio alone.

Regional Outlook

North America and Europe

• North America reached USD 13.6 billion in 2025, including USD 11.6 billion from the United States, and will reach USD 43.2 billion by 2035 at a 12.21% CAGR.
• The region’s supplement market, direct-to-consumer infrastructure, and specialty retail support demand, while FDA dietary-supplement oversight shapes labeling and structure-function claims.
• Canada provides a smaller but regulated natural-health-product market; North American buyers will continue to favor cGMP processes, active-content testing, and recognized certifications.
• Europe was the fastest-growing region and will grow from USD 13.1 billion in 2025 to USD 43.9 billion by 2035 at a 12.83% CAGR.
• Germany, the United Kingdom, France, Spain, and Italy form the major European demand centers across supplements, cosmetics, and functional food.
• European Food Safety Authority review processes and the Novel Food framework raise the entry threshold for botanical ingredients while favoring qualified, traceable supply.
• Through 2030, Europe will reward high-specification extracts more strongly than lower-priced commodity grades.
• Regional performance reflects cultivation and extraction capacity, regulatory thresholds, consumer-health spending, and channel maturity.

Asia Pacific, Latin America, and Middle East & Africa

• Asia Pacific was the largest region, reaching USD 15.8 billion in 2025 and projected to reach USD 53.3 billion by 2035 at a 12.90% CAGR.
• China anchors cultivation, extraction, and domestic demand, while India adds manufacturing diversification and expanding nutraceutical consumption.
• Japan, South Korea, and Australia contribute high-value cosmetics, functional-food, and supplement demand.
• China’s Shaanxi Province concentrates Shaanxi Bolin Biotechnology, Shaanxi Hongda Phytochemistry, Shaanxi SCIGROUND Biotechnology, and Xi'an Lanshan Biotechnology.
• India offers alternative sourcing through Phytotech Extracts, Jeeva Organic, and Nans Products; by 2028, supplier diversification will be a commercial requirement for buyers that need resilience as well as cost efficiency.
• Latin America reached USD 6.6 billion in 2025 and will grow to USD 20.8 billion by 2035 at a 12.20% CAGR, with Brazil and Mexico the principal markets.
• The Middle East and Africa market reached USD 2.3 billion in 2025 and will reach USD 6.3 billion by 2035 at a 10.57% CAGR.
• Saudi Arabia and the UAE offer higher-value Gulf demand, while South Africa is the most developed sub-Saharan market; WHO regional diabetes burden supports targeted wellness demand in selected urban centers.

Competitive Landscape

Structure and recent moves

• Shaanxi Bolin Biotechnology led the market with a 9.8% share in 2025, while the top five held 38.5% collectively and the remaining 61.5% stayed fragmented.
• The top five participants were Shaanxi Bolin Biotechnology, Shaanxi Hongda Phytochemistry, ETChem (Suzhou), Shaanxi SCIGROUND Biotechnology, and Naturalin Bio-Resources.
• Bolin’s August 2025 organic-certified extraction-facility commissioning expanded production capacity by 200%, strengthening pharmaceutical-grade and premium supplement supply.
• Shaanxi Hongda Phytochemistry competes through vertically integrated cultivation and specifications spanning DNJ, flavonoid, and polyphenol needs.
• ETChem (Suzhou) brings diversified natural-ingredient processing and global distribution, although a specific white mulberry leaf extract SKU listing was not confirmed in the approved evidence package.
• Shaanxi SCIGROUND Biotechnology is a newer Xi'an-cluster supplier with commercial DNJ 1 to 5% and 10:1 products.
• Naturalin Bio-Resources introduced a 30% DNJ extract in November 2025, positioning around active-content density and functional-food relevance.
• Nutra Green Biotechnology offers 10:1, 1-DNJ 1%, and flavones 5% grades, while Tong Rui Bio-Tech and Undersun Biomedtech rely on integrated processing depth.
• Mergers, partnerships, and capacity investments are likely to intensify from 2027 to 2030 as pharmaceutical-intent demand raises the cost of credible supply.
• Brevintel analysis finds competitive concentration remaining moderate through 2030, with a two-tier split between high-DNJ, organic, pharmaceutical-intent supply and commodity powder.

Integrated producers

• Shaanxi Bolin Biotechnology
• Shaanxi Hongda Phytochemistry
• ETChem (Suzhou)
• Tong Rui Bio-Tech
• Undersun Biomedtech

Specialty suppliers

• Shaanxi SCIGROUND Biotechnology
• Naturalin Bio-Resources
• Phytotech Extracts
• Jeeva Organic
• Nutra Green Biotechnology
• Nans Products
• Xi'an Lanshan Biotechnology
• TOKIWA PHYTOCHEMICAL